How does Creative Biolabs select the appropriate respiratory disease animal model based on research objectives?

Choosing an effective model requires a comprehensive assessment of the particular disease, research aims, and translational needs. This approach is exemplified by the use of the ovalbumin-sensitized mouse model for asthma studies, the cigarette smoke-exposed rat model for COPD, and various models for acute lung injury in ARDS research. Such evaluations facilitate model applicability analyses and recommendations that are closely aligned with specific research objectives.

How does Creative Biolabs ensure the stability and reproducibility of your models?

We strictly adhere to standardized procedures, meticulously controlling every stage, from the selection and husbandry of experimental animals, the source, dosage, and administration route of modeling compounds, to the definition of key model evaluation endpoints. Through extensive preliminary experiments and data analysis, we define the optimal parameter ranges for model induction, minimizing the impact of individual variations on model stability. Validated through long-term application, our models show minimal batch-to-batch variation and high data reliability. We've successfully provided preclinical Contract Research Organization (CRO) services to numerous pharmaceutical companies, contributing to the approval of multiple clinical trials.

What are the core modeling technologies used in constructing respiratory disease models?

The core modeling techniques include chemical induction, immune stimulation, mechanical injury, and gene editing. We have mastered these techniques and continually optimize them to enhance model quality for pharmacology and pharmacodynamic studies.

Does Creative Biolabs' team have the capability to perform complex experimental techniques?

Yes. Creative Biolabs' team exhibits extensive expertise in advanced experimental techniques, spanning several key areas. For example, molecular biology (e.g., bioinformatics analysis and proteomics), cell biology (e.g., cell culture, cell transfection, and cell functional assays), intricate surgical procedures (e.g., lobectomy and tracheal intubation), and cutting-edge imaging technologies.

Respiratory Disease Modeling & Pharmacodynamics Services

Introduction

Respiratory diseases, such as pneumonia, chronic obstructive pulmonary disease (COPD), rhinitis, asthma, cystic fibrosis (CF), pulmonary hypertension (PH), idiopathic pulmonary fibrosis (IPF), and tuberculosis (Tbc), contribute to 7% of global mortality annually. Primary pathogenic factors encompass allergen exposure, bacterial and viral pathogens, tobacco smoke, immunodeficiency, and genetic susceptibilities. Creative Biolabs has developed a variety of refined respiratory system animal models using diverse methodologies to accurately replicate the pathophysiological characteristics of respiratory diseases, which play a crucial role in advancing the R&D of pharmaceuticals. Furthermore, they provide verification methods for preclinical assessments of diverse therapeutic agents, including vaccines, small molecules, biological products, as well as nanobodies, gene therapies, and cell therapies.

Fig.1 Mechanism of LPS induced ARDS. (OA Literature) Fig.1 Exposure to LPS resulted in excessive neutrophil infiltration and significant lung tissue injury.^1,4

Fig.2 An example of a mouse model of COPD. (OA Literature) Fig.2 Schisandrin A modulates the Nrf2 signaling pathway to suppress NLRP3 inflammasome activation, thereby inhibiting cellular pyroptosis.^2,4

Available Respiratory System Disease Models

Creative Biolabs' existing well-characterized respiratory disease models for preclinical research include rodent, non-rodent, and non-human primates. Learn more about these models by clicking on the links below.

Allergic Asthma Models

Ovalbumin induced Asthma Model
HDM induced Allergic Asthma Model
MC903 & Ovalbumin induced Asthma Model
OVA & HDM induced Asthma Model

Non-Allergic Asthma Models

LPS & Ozone induced Asthma Model
IL-17/TH17-Driven Asthma Model
Poly(I:C) induced Acute Lung Injury Models
Obesity-Related Asthma Model

Chemically induced Pulmonary Fibrosis Models

Bleomycin induced Pulmonary Fibrosis Model
Silica induced Pulmonary Fibrosis Model
Paraquat induced Pulmonary Fibrosis Model
Asbestos induced Pulmonary Fibrosis Model

Genetic & Transgenic Pulmonary Fibrosis Models

TGF-beta Transgenic Mouse Pulmonary Fibrosis Model
SP-C Mutant Mouse Pulmonary Fibrosis Model
Telomerase-Deficient Mouse Pulmonary Fibrosis Model

Immunologically driven Pulmonary Fibrosis Models

Adoptive Transfer of Fibrocytes Model
IL-13/IL-17 Overexpression Induced Pulmonary Fibrosis Model

Lung Injury/Pneumonia Models

LPS induced Pulmonary Neutrophilia Model
LPS induced Acute Lung Injury Models
Sephadex Ged induced Acute Lung Injury (ALI) Model
High Oxygen Environment induced Acute/Chronic Lung Injury Model
Papain induced Acute Lung Injury Models
TNF-α and IL-17A induced Acute Lung Injury Model
Immune Complex induced Acute Lung Injury Model
A. Baumanii-infected Pneumonia Model
Poly (I:C) induced Acute Lung Injury Model

COPD Models

Cigarette Smoke induced COPD Model
Cigarette Smoking & LPS induced COPD Mouse Model

Pulmonary Emphysema Models

PPE induced Pulmonary Emphysema Models
Human Neutrophil Elastase (HNE) Model

Pulmonary Edema Models

LPS induced Pulmonary edema Model
Unilateral Nephrectomy & DOCA induced Nephrogenic Pulmonary Edema Model
Epinephrine/Norepinephrine induced Acute Cardiogenic Pulmonary Edema Model

Airway Models

IL-13 induced Airway Mucus Hypersecretion Models
Acetylcholine induced Airway Constriction Models
Pseudomonas Aeruginosa induced Bronchiectasis Model

Cough Models

Citric Acid induced Cough Model
Citric Acid & ATP induced Cough Model
Citric Acid & Histamine induced Cough Model
Citric Acid &OVA induced Cough Model
Citric Acid & Respitose induced Cough Model
Capsaicine induced Cough Model
Cinnamyl Aldehyde induced Cough Model

Pulmonary Hypertension Models

Monocrotaline induced Pulmonary Hypertension Model
Hypoxia induced Pulmonary Hypertension Model

Allergic Rhinitis Models

OVA induced Allergic Rhinitis Model
HDM induced Allergic Rhinitis Model

Non-Allergic Rhinitis Models

Capsaicin induced Neurogenic Rhinitis Model

Pulmonary Nodular Disease Models

SiO₂ induced Pulmonary Nodule Model
Carbon nanoparticle induced sarcoidosis model

Fig.3 Available animal models in chronic respiratory diseases. (OA Literature) Fig.3 Mammalian and invertebrate models available to study the chronic respiratory diseases.^3,4

Evaluation Platform

Animals: Mouse, Rat, Hamster, Rabbit, Cat, Dog, NHPs.
Measurements
To thoroughly assess pharmacology and efficacy, ensuring scientific accuracy and data reliability, Creative Biolabs has established the following platforms:
- Clinical Symptom and Sign Monitoring: This platform conducts evaluations of body weight changes, activity levels, survival status, respiratory function, pulmonary function tests, and gas exchange efficiency.
- Histopathological Analysis: Histopathological evaluation is conducted using anatomical techniques and various staining methods, including H&E staining, PAS staining, Masson's trichrome staining, immunohistochemistry (IHC), indirect immunofluorescence (IF), TUNEL staining, and the comet assay.
- Molecular Biology and Immunology Detection: This platform facilitates the detection of genes and immune cells through techniques such as RT-qPCR, digital PCR, in situ hybridization (ISH), flow cytometry, MSD, next-generation sequencing, and high-throughput screening.
- Imaging and In Vivo Dynamic Monitoring: The progression or scope of lesions is detected via small animal ultrasound, in vivo imaging, and Micro-CT.

Our advantages

Professional technical capabilities: Our technical team comprises members with diverse and complementary professional backgrounds, with extensive knowledge and practical experience in areas such as respiratory pharmacology, anti-inflammatory and immunomodulatory drug development, and inhalable formulation development. Our team holds a leading position in respiratory disease drug development and preclinical evaluation, providing comprehensive and professional technical support for all projects.
Diversity of detection platforms: We introduce internationally advanced testing instruments and offer advanced detection methods. This enables the comprehensive evaluation of inflammatory factors, histopathology, and immunology, thereby ensuring accuracy and professionalism in efficacy assessments.
Project management capabilities: We have a project management team that works flexibly with project scientists and experimental technicians, adeptly handling challenges during project implementation, ensuring efficient and high-quality project completion.
Service flexibility and customization: We offer tailored model services based on individual client R&D requirements and specific model characteristics, allowing for flexible adjustments during project execution to meet diverse customer needs.
One-stop service: Our comprehensive services encompass all facets of preclinical research on respiratory diseases, including pharmacodynamic, toxicological, and pharmacokinetic research. This approach eliminates the need for multiple suppliers, saving time and effort while enhancing research and development efficiency.

Work with Us

Inquiry Stage:

Summarize the project requirements and fill in the information collection form.
Sign a CDA from both parties to further communicate information, such as targets.
Select an animal model, discuss experimental design, and determine assay parameters.
Project costing and project schedule forecasting.

Project Start:

We provide a detailed project plan, including the required sample quantities, methods, and protocols.
Both parties confirm the project details and start the project.
Confirm the timeline of the project.

Project Progress:

We provide periodic results and information on the animal's condition.
We will work together to make project adjustments as necessary.

Project Completion:

We provide a comprehensive project report promptly.
We arrange transportation for the produced samples.
We provide a discussion of the project results and help to arrange the next steps.

After-Sales Support:

Data storage and archiving.

Get in touch!

FAQs

Q. How does Creative Biolabs select the appropriate respiratory disease animal model based on research objectives?

A: Choosing an effective model requires a comprehensive assessment of the particular disease, research aims, and translational needs. This approach is exemplified by the use of the ovalbumin-sensitized mouse model for asthma studies, the cigarette smoke-exposed rat model for COPD, and various models for acute lung injury in ARDS research. Such evaluations facilitate model applicability analyses and recommendations that are closely aligned with specific research objectives.
Q. How does Creative Biolabs ensure the stability and reproducibility of your models?

A: We strictly adhere to standardized procedures, meticulously controlling every stage, from the selection and husbandry of experimental animals, the source, dosage, and administration route of modeling compounds, to the definition of key model evaluation endpoints. Through extensive preliminary experiments and data analysis, we define the optimal parameter ranges for model induction, minimizing the impact of individual variations on model stability. Validated through long-term application, our models show minimal batch-to-batch variation and high data reliability. We've successfully provided preclinical Contract Research Organization (CRO) services to numerous pharmaceutical companies, contributing to the approval of multiple clinical trials.
Q. What are the core modeling technologies used in constructing respiratory disease models?

A: The core modeling techniques include chemical induction, immune stimulation, mechanical injury, and gene editing. We have mastered these techniques and continually optimize them to enhance model quality for pharmacology and pharmacodynamic studies.
Q. Does Creative Biolabs' team have the capability to perform complex experimental techniques?

A: Yes. Creative Biolabs' team exhibits extensive expertise in advanced experimental techniques, spanning several key areas. For example, molecular biology (e.g., bioinformatics analysis and proteomics), cell biology (e.g., cell culture, cell transfection, and cell functional assays), intricate surgical procedures (e.g., lobectomy and tracheal intubation), and cutting-edge imaging technologies.

Published Data

The effect of Indole-3-carbinol (I3C) in acute respiratory distress syndrome (ARDS) induced by LPS: Following 48-hour treatment with LPS or LPS + I3C, murine pulmonary immune cells analysis demonstrated that I3C directly suppressed the infiltration of both CCR²⁺ monocytes and CXCR²⁺ neutrophils within the lung.

Fig.4 An ARDS model induced by LPS. (OA Literature) Fig.4 LPS exposure leads to an expansion of both CXCR²⁺ monocyte and CXCR²⁺ neutrophil populations, an effect that is significantly attenuated by I3C treatment.^1,4

References

Holloman, Bryan Latrell et al. "Indole-3-carbinol attenuates lipopolysaccharide induced acute respiratory distress syndrome through activation of AhR: role of CCR2+ monocyte activation and recruitment in the regulation of CXCR2+ neutrophils in the lungs." Frontiers in Immunology vol. 15 1330373. https://doi.org/10.3389/fimmu.2024.1330373
Zeng, Jiamin et al. "Schisandrin A regulates the Nrf2 signaling pathway and inhibits NLRP3 inflammasome activation to interfere with pyroptosis in a mouse model of COPD." European Journal of Medical Research vol. 28,1 217. https://doi.org/10.1186/s40001-023-01190-8
Fröhlich, Eleonore. "Animals in Respiratory Research." International Journal of Molecular Sciences vol. 25,5 2903. https://doi.org/10.3390/ijms25052903
Distributed under Open Access license CC BY 4.0, without modification.